Supplementary Data — Regdanvimab reduced COVID-19 risk: real-time meta analysis of 12 studies

@CovidAnalysis, November 2025, Version 11V11
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Lee 59% 0.41 [0.02-10.1] death 0/234 1/544 Improvement, RR [CI] Treatment Control Lee (PSM) 82% 0.18 [0.06-0.52] severe case 234 (n) 234 (n) Lee (PSM) 45% 0.55 [0.30-1.00] oxygen 234 (n) 234 (n) Lee 8% 0.92 [0.87-0.97] no disch. 234 (n) 544 (n) Lee 77% 0.23 [0.09-0.58] no disch. 5/234 50/544 Streinu-.. (DB RCT) -151% 2.51 [0.10-61.1] ventilation 1/203 0/104 Streinu-.. (DB RCT) 54% 0.46 [0.18-1.15] oxygen 8/203 9/104 Streinu-.. (DB RCT) 49% 0.51 [0.21-1.25] hosp. 9/203 9/104 Streinu-.. (DB RCT) 49% 0.51 [0.21-1.25] progression 9/203 9/104 Streinu-.. (DB RCT) 35% 0.65 [0.49-0.86] recov. time 203 (n) 104 (n) Streinu-.. (DB RCT) 2% 0.98 [0.81-1.20] viral time 203 (n) 104 (n) Chae 71% 0.29 [0.01-5.76] death 0/25 2/99 Chae 64% 0.36 [0.05-2.66] ventilation 1/25 11/99 Chae 9% 0.91 [0.68-1.23] hosp. time 25 (n) 99 (n) Park (PSM) 79% 0.21 [0.12-0.34] progression 19/377 81/377 Park (PSM) 13% 0.87 [0.83-0.91] hosp. time 377 (n) 377 (n) Jang 60% 0.40 [0.26-0.63] oxygen 17/73 79/137 Jang 44% 0.56 [0.33-0.94] no disch. 14/73 47/137 Jang 35% 0.65 [0.50-0.85] no disch. 34/73 98/137 Jang 13% 0.87 [0.79-0.96] hosp. time 73 (n) 137 (n) Kim (DB RCT) 50% 0.50 [0.05-5.53] death 1/656 2/659 Kim (DB RCT) 86% 0.14 [0.01-2.77] ventilation 0/656 3/659 Kim (DB RCT) 91% 0.09 [0.01-1.64] ICU 0/656 5/659 Kim (DB RCT) 69% 0.31 [0.17-0.54] oxygen 15/656 49/659 Kim (DB RCT) 69% 0.31 [0.18-0.54] hosp. 16/656 52/659 Kim (DB RCT) 70% 0.30 [0.18-0.52] progression 16/656 53/659 Kim (DB RCT) 72% 0.28 [0.16-0.51] progression 14/446 48/434 Kim (DB RCT) 32% 0.68 [0.60-0.77] viral+ 612 (n) 618 (n) Jang 70% 0.30 [0.01-7.25] death 0/418 1/304 Jang 12% 0.88 [0.84-0.92] hosp. time 418 (n) 304 (n) Jang 49% 0.51 [0.41-0.64] oxygen 92/418 130/304 Jang 68% 0.32 [0.22-0.48] no disch. 31/418 70/304 Kim 51% 0.49 [0.34-0.71] progression 1,095 (n) 1,119 (n) Kim 34% 0.67 [0.35-1.27] progression 1,095 (n) 1,119 (n) Kim 32% 0.68 [0.56-0.82] oxygen 1,095 (n) 1,119 (n) Kim 4% 0.96 [0.70-1.33] oxygen 1,095 (n) 1,119 (n) Fomina -415% 5.15 [1.46-18.2] viral+ 7/24 3/53 OT​1​ Hwang 83% 0.17 [0.02-1.37] death 1/189 6/189 Hwang 92% 0.08 [0.01-0.78] death 0/189 6/189 Hwang 0% 1.00 [0.06-15.9] ventilation 1/189 1/189 Hwang 33% 0.67 [0.28-1.59] ICU 8/189 12/189 Hwang 55% 0.45 [0.25-0.82] oxygen 14/189 31/189 Lee 59% 0.41 [0.22-0.76] death 10/77 49/153 Choi 86% 0.14 [0.01-2.56] death 0/65 5/333 Choi 76% 0.24 [0.07-0.60] oxygen 4/65 67/333 Regdanvimab COVID-19 outcomes c19early.org November 2025 ​1​ OT: comparison with other treatment Favors regdanvimab Favors control
Fig. S1. All outcomes.
Loading..
Fig. S2. Comparison of results for RCTs versus observational studies. For COVID-19 treatments, there is no significant difference between the results of RCTs and observational studies. Observational studies do not systematically over or underestimate efficacy. For high-cost treatments, there is a non-significant trend towards RCTs showing greater efficacy.